Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 13 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11858927

    Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

    HEPAREGENIX GMBH · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  2. US 11858930

    Fused bicyclic RAF inhibitors and methods for use thereof

    Jazz Pharmaceuticals Ireland Limited · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  3. US 11858915

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  4. US 11858957

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  5. US 11858937

    Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors

    Lead Discovery Center GmbH · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  6. US 11858925

    GAS41 inhibitors and methods of use thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  7. US 11851443

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  8. US 11851449

    Heterocyclic amide compounds having an RORvt inhibitory action

    Takeda Pharmaceutical Company Limited · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  9. US 11845747

    Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  10. US 11844799

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  11. US 11844801

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  12. US 11845989

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  13. US 11845808

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Protagonist Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  14. US 11844779

    PKC-Delta-I inhibitor formulations and uses thereof

    United States Government as represented by the Department of Veterans Affairs · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  15. US 11840540

    Dimers of covalent NFKB inhibitors

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  16. US 11840536

    Heterocyclic inhibitors of PTPN11

    The Board of Regents of the University of Texas System · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  17. US 11840525

    Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer

    NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  18. US 11834515

    Macrocyclic compounds as proteasome inhibitors

    Tri-Institutional Therapeutics Discovery Institute, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  19. US 11834436

    Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  20. US 11833160

    Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases

    UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  21. US 11833210

    ASH1L inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  22. US 2023381101

    AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 30, 2023 · Expires Nov 25, 2043

    granted
  23. US 11826408

    CD200 inhibitors and methods of use thereof

    Regents of the University of Minnesota · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  24. US 11827637

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted